Clinical trials: Plasmodium Falciparum Malaria
Malaria
Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated P.Falciparum Malaria in Children
This is an open label uncontrolled study to determine the efficacy of fosmidomycin and clindamycin when co-administered orally over three days in the treatment of acute uncomplicated Plasmodium falciparum malaria in children.
- Trial name
- NCT01464138
- Testing
- Fosmidomycin and Clindamycin co-administration
- Where
- Mozambique
- Volunteers
- 52 people
- Sponsor
- Jomaa Pharma GmbH
LLIN, PBO LLIN, IRS, Larviciding
Adaptive Interventions for Optimizing Malaria Control: a Cluster-Randomized SMART Trial
In the past decade, massive scale-up of long-lasting insecticidal nets (LLINs) and indoor residual spraying (IRS) have led to significant reductions in malaria mortality and morbidity.
- Trial name
- NCT04182126
- Testing
- Regular long-lasting insecticidal nets, LLIN plus Piperonyl butoxide-treated LLIN, Long-lasting microbial larvicide
- Where
- 2 sites in United States, Kenya
- Volunteers
- 122,872 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Uncomplicated Plasmodium Falciparum
Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patients in Southwest Sumba Regency
Currently, the first-line combination of artemisinin, piperaquine and prima-quine is quite effective in controlling malaria, however, the threat of spread of drug-resistant parasites has been reported.
- Trial name
- MCHUPF (NCT05829187)
- Testing
- Dihydroartemisinin, Piperaquine, Primaquine
- Where
- Indonesia
- Volunteers
- 36 people
- Sponsor
- Syamsudin Abdillah,Ph.D, Pharm D
Malaria
Chlorproguanil-Dapsone in Pregnant Women
Controlling malaria during pregnancy is a vital strategy in decreasing maternal and child mortality in Africa. There are data from clinical trials and program evaluations in stable transmission areas that show that intermittent…
- Trial name
- NCT00126971
- Testing
- chlorproguanil-dapsone
- Where
- Mali
- Volunteers
- 132 people
- Sponsor
- Centers for Disease Control and Prevention
Malaria, Plasmodium Falciparum Malaria
Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis
TÜCHMI-002 is a single center, randomized, placebo-controlled, double-blinded, PfSPZ Challenge dose finding trial with two chemoprophylactic regimens and subsequent controlled human malaria infection (CHMI).
- Trial name
- NCT02115516
- Testing
- PfSPZ Challenge
- Where
- Germany
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria, Asymptomatic Malaria
Low Dose Primaquine for Clearance of Gametocytes
Primaquine (PQ) is currently the only available drug that can clear mature transmission stages of P. falciparum parasites. PQ was previously shown to clear gametocytes that persist after artemisinin-combination therapy.
- Conditions
- Malaria, Asymptomatic Malaria, Plasmodium Falciparum
- Trial name
- LOPRIM (NCT01935882)
- Testing
- Artemether-lumefantrine combination, Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine, Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine
- Where
- Burkina Faso
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
Efficacy, Safety and Pharmacokinetic of ArtequinTM P. Falciparum Malaria
Treatment of Plasmodium falciparum malaria in Africa is increasingly difficult. Resistance to cheap efficient antimalarial drugs poses an increasing threat.
- Trial name
- NCT00243737
- Testing
- Artesunate-Mefloquine
- Where
- 2 sites in Gabon
- Volunteers
- 70 people
- Sponsor
- Albert Schweitzer Hospital
Plasmodium Falciparum
Clinical Trial of the PfSPZ Vaccine
The purpose of this study is to determine the safety and tolerability of a non-replicating, metabolically active Plasmodium falciparum sporozoite (PfSPZ) vaccine in malaria-naïve healthy volunteers following multiple-dose…
- Trial name
- NCT01001650
- Testing
- Plasmodium falciparum Sporozoite (strain NF-54; Anopheles stephensi mosquitoes) Vaccine, Live, Inactivated (gamma irradiation)
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria, Falciparum
Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria
The purpose of this study is to determine the tolerability and pharmacokinetics of Sevuparin/DF02 when administered as an i.v. infusion in combination with Malanil® (atovaquone/proguanil) as anti-malarial treatment in subjects…
- Trial name
- NCT01442168
- Testing
- Sevuparin sodium + atovaquone/proquanil, atovaquone/proquanil
- Where
- 3 sites in Thailand
- Volunteers
- 53 people
- Sponsor
- Modus Therapeutics AB
Malaria, Malaria, Falciparum
Efficacy of Combined PEV3A Virosomal Vaccine and FP9-MVA ME-TRAP Prime Boost Regimen
The purpose of this study is to test three candidate malaria vaccines in new combinations to assess their efficacy at preventing malaria infection and triggering immune responses against malaria.
- Trial name
- NCT00408668
- Testing
- PEV3A, FP9 ME-TRAP, MVA ME-TRAP
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Plasmodium Falciparum Malaria
Fetal Immunity to Falciparum Malaria
The purpose of this study is to find out what effect malaria in the mother has on the development of her child's immune system response to malaria and whether being exposed to malaria in the womb makes a child more likely to get…
- Trial name
- NCT00314899
- Where
- Kenya
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Markers of T Cell Suppression: Associations With Malaria Infection and Antimalarial Treatment in Malian Children
Background: The disease malaria can cause very serious health problems. Researchers want to see if malaria affects the way T cells and vaccines work in the body.
- Trial name
- NCT02504918
- Where
- Mali
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Plasmodium Falciparum Malaria
Rapid Diagnostic Tests for Assessment of Initial Clearance and Detection of Recurrent Malaria Infections
The aim of the study was to follow clearance of malaria infections and detection of new malaria episodes after initiation of antimalarial treatment in Tanzanian children.
- Trial name
- NCT01843764
- Testing
- HRP2 and LDH based rapid diagnostic tests for P.falciparum
- Where
- 2 sites in Tanzania
- Volunteers
- 53 people
- Sponsor
- Anders Björkman
Prophylaxis Against Plasmodium Falciparum Malaria
A Study of Safety and Immunogenicity of a Malaria Vaccine Candidate
Shanghai Wanxing Bio-Pharmaceuticals is currently evaluating one malaria vaccine candidate, PfCP2.9 adjuvanted with Montanide ISA 720.
- Trial name
- NCT00284973
- Testing
- Plasmodium falciparum Chimeric Prot. 2.9 - Montanide ISA 720
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Shanghai Wanxing Bio-Pharmaceutical Co. Ltd.
Malaria Fever
A Challenge Study to Assess the Blood-stage Efficacy of Full-length SUM-101 Malaria Vaccine Candidate
The goal of the study is to test the efficacy using a homologous CHMI of this vaccine candidate early in the development path in a population living in malaria-endemic areas.
- Trial name
- CHMI-SUM-101 (NCT07124156)
- Testing
- SUM-101, CHMI, Verorab®
- Sponsor
- European Vaccine Initiative
Malaria
Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites in Healthy African Adults in Mali
Background: Malaria is still a health problem in Sub-Saharan Africa. Death rates are stable and have even increased in some areas. There are malaria vaccines.
- Trial name
- NCT02627456
- Testing
- PfSPZ Vaccine, PfSPZ Challenge Material, PBS and HSA Diluent
- Where
- Mali
- Volunteers
- 409 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
First-in-Human Study of an Oral Plasmodium Falciparum Plasma Membrane Protein Inhibitor
Malaria is an infectious disease caused by a parasite that is passed to humans when an infected mosquito bites a person. About 3.4 billion people live in areas of the world where malaria is regularly found.
- Trial name
- NCT02661373
- Testing
- SJ733, Cobicistat
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- St. Jude Children's Research Hospital
Malaria
Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Malaria
The purpose of this study is to determine the efficacy of pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children.
- Trial name
- PAAL (NCT02411994)
- Testing
- Pyronaridine-artesunate, Artemether-lumefantrine combination
- Where
- Kenya
- Volunteers
- 197 people
- Sponsor
- Royal Tropical Institute
Plasmodium Falciparum Malaria
CS DNA MVA Trial in Mampong, Ghana
The purpose of this study is to evaluate the safety, tolerability, and effectiveness of 2 doses of a malaria vaccine (DNA) followed by a dose of another type of malaria vaccine (MVA) given as a "booster." Forty-eight adults in…
- Trial name
- NCT00377494
- Testing
- MVA-CSO Vaccine, PfCSP DNA (VCL-2510) Vaccine
- Where
- 2 sites in United States, Ghana
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
The study intends to establish proof of concept for a fractional dose schedule under conditions of natural exposure in children 5-17 months old at first vaccination.
- Trial name
- NCT03276962
- Testing
- RTS,S/AS01E (Full dose), RTS,S/AS01E (1/5th dose), Rabies vaccine
- Where
- 2 sites in Ghana, Kenya
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline